From 26-30 August 2017, leading experts from across the globe will convene in Barcelona for the world’s largest cardiovascular congress, ESC Congress 2017.
Conversation at this year’s congress will cover a range of topics and will continue to look at how the treatment of cardiovascular disease can be improved and optimized for patients and physicians; while major strides have been made in the area of blood clot management, unmet needs do still remain. With over 32,000 attendees expected, ESC Congress 2017 represents a unique opportunity for experts in the field to openly discuss how we can advance blood clot management. At Bayer, we are proud to play a role in contributing to this dialogue and continuing to address the unmet needs of patients in a range of disease areas through our clinical development program.
Bayer will be presenting data from 17 abstracts on blood clot management at ESC Congress 2017 from a range of clinical trials and real-world studies in late-breaking, poster and oral presentations. These data explore unmet needs in a variety of patient populations, including those with coronary artery disease (CAD) and peripheral artery disease (PAD), an area in which non-vitamin K antagonist oral anticoagulants (NOACs) have previously not been investigated.
ESC Congress 2017 Comments from Experts both Bayer and Academia
“Despite the major clinical advances of the past decade, there remain important unmet needs for patients at risk of blood clots. At Bayer, our journey in blood clot management continues and we are committed to investigating how our therapies can benefit those patients who may currently have limited treatment options or for whom existing therapies can be optimized. We are excited to once again be part of ESC Congress 2017 and are looking forward to not only sharing the latest data from our clinical development program but also hearing from other experts in the field of cardiology.”
Martin van Eickels, Head of Global Medical Affairs Thrombosis and Ophthalmology, Bayer, Germany
“CAD represents a significant health burden worldwide and led to an estimated 8.8 million deaths in 2015. Furthermore, approximately 202 million people worldwide are affected by PAD, an important risk marker for heart disease. These numbers are only expected to increase as the population ages and there is a critical need to define better therapeutic options for those patients with CAD and PAD who remain at risk of ischemic events.”
Dr John Eikelboom, Associate Professor of Medicine, McMaster University, Canada
“As the leading cardiology forum for scientific exchange and discovery, ESC Congress 2017 represents an important opportunity for the best minds in the community to come together with the goal of addressing remaining unmet needs for patients. At Bayer, we are proud to be part of this year’s Congress, and to be presenting seminal new data from our clinical study program, which reflect our commitment to improving the lives of patients with cardiovascular disease.”
Dr Frank Misselwitz, Vice President and Head Therapeutic Areas Thrombosis & Hematology, Bayer